Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics

References

• World Health Organization. Neurological disorders: a public health approach. Geneva: WHO Press; 2006.
   Google Scholar
• Dumas ME, Davidovic L. Metabolic profiling and phenotyping of central nervous system diseases: metabolites bring insights into brain dysfunctions. J Neuroimmune Pharmacol. 2015;10:402–424.
   PubMed Web of Science ®Google Scholar
• Lei S, Powers R. NMR metabolomics analysis of Parkinson’s disease Shulei. Curr Metabol. 2013;1:191–209.
   PubMedGoogle Scholar
• Qi Z, Yu GP, Tretter F, et al. A heuristic model for working memory de fi cit in schizophrenia ☆. BBA Gen Subj [Internet]. 2016;1860:2696–2705.
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–715.
   PubMed Web of Science ®Google Scholar
• Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov [Internet]. 2007;6:521–532. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17599084
   PubMed Web of Science ®Google Scholar
• Soares HD. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development. Curr Opin Investig Drugs. 2010;11:795–801.
   PubMedGoogle Scholar
• Ringel M, Tollman P, Hersch G, et al. Does size matter in R&D productivity? If not, what does? Nat Rev Drug Discov [Internet]. 2013;12:901–902. Available from: http://www.nature.com/doifinder/10.1038/nrd4164
   PubMed Web of Science ®Google Scholar
• Geerts H. Of mice and men bridging the translational disconnect in CNS drug discovery. CNS Drugs. 2009;23:915–926.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Krishnan KRR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology. 2009;34:173–186.
   PubMed Web of Science ®Google Scholar
• de Lange ECM, Ravenstijn PGM, Groenendaal D, et al. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. Aaps J. 2005;7:E532–E543.
   PubMed Web of Science ®Google Scholar
• Morgan P, van der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today [Internet]. 2012;17:419–424.
   PubMed Web of Science ®Google Scholar
• Breimer DD, Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The “wooden shoe’ paradigm. Clin Pharmacokinet. 1997;32:259–267.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Weinshilboum RM. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther [Internet]. 2014;95:154–167. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24193171
   PubMed Web of Science ®Google Scholar
• Pratt J, Winchester C, Dawson N, et al. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov [Internet]. 2012;11:560–579. Available from: http://www.nature.com/doifinder/10.1038/nrd3649
   PubMed Web of Science ®Google Scholar
• Hall AM, Roberson ED. Mouse models of Alzheimer ’ s disease. Brain Res Bull [Internet]. 2012;88:3–12. Available from: http://rd.springer.com/chapter/10.1007/978-1-84628-440-3_16
   PubMed Web of Science ®Google Scholar
• Danhof M, de Lange ECM, Della Pasqua OE, et al. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008;29:186–191.
   PubMed Web of Science ®Google Scholar
• Hurko O. The uses of biomarkers in drug development. Ann N Y Acad Sci. 2009;1180:1–10.
   PubMed Web of Science ®Google Scholar
• Wong DF, Potter WZ, Brasic JR. Proof of concept: functional models for drug development in humans. Neuropsychopharmacol Fith Gener Prog [Internet]. 2002;457–473. Available from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.95.4307&rep=rep1&type=pdf.
   Google Scholar
• Pich EM, Vargas G, Domenici E. Biomarkers for antipsychotic therapies. Handb Exp Pharmacol Curr Antipsychotics. 2012;212:339–360.
   Google Scholar
• Lesko L, Atkinson A. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001;41:347–366.
   PubMed Web of Science ®Google Scholar
• Atkinson AJJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
   PubMed Web of Science ®Google Scholar
• Johnson M, Kozielska M, Reddy VP, et al. Translational modeling in schizophrenia : predicting human dopamine D 2 receptor occupancy. Pharm Res. 2016;33:1003–1017.
   Google Scholar
• Garner R, Gopalakrishnan S, McCauley JA, et al. Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist. Pharmacol Res Perspect [Internet]. 2015;3:e00198. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777252/
   PubMed Web of Science ®Google Scholar
• Wong YC, Ilkova T, van Wijk RC, et al. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat. Eur J Pharm Sci. 2017;111:514–525.
   Web of Science ®Google Scholar
• Borsook D, Becerra L, Fava M. Use of functional imaging across clinical phases in CNS drug development. Transl Psychiat [Internet]. 2013;3:e282.
   PubMed Web of Science ®Google Scholar
• Borsook D, Hargreaves R, Becerra L. Can functional magnetic resonance imaging improve success rates in CNS drug discovery? Expert Opin Drug Discov. 2011;6:597–617.
   PubMed Web of Science ®Google Scholar
• Groenendaal D, Freijer J, de Mik D, et al. Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG. Br J Pharmacol. 2007;151:713–720.
   PubMed Web of Science ®Google Scholar
• Cox EH, Langemeijer MW, Gubbens-Stibbe JM, et al. The comparative pharmacodynamics of remifentanil and its metabolite GR90291, in a rat electroencephalogrphic model. Anesthesiology. 1999;90:535–544.
   PubMed Web of Science ®Google Scholar
• Stevens J, Ploeger BA, Hammarlund-Udenaes M, et al. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. J Pharmacokinet Pharmacodyn. 2012;39:463–477.
   PubMed Web of Science ®Google Scholar
• Danhof M, Alvan G, Dahl SG, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res. 2005;22:1432–1437.
   PubMed Web of Science ®Google Scholar
• Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 2009;24:16–24.
   PubMed Web of Science ®Google Scholar
• de Lange ECM, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet [Internet]. 2002;41:691–703. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12162757
   PubMed Web of Science ®Google Scholar
• Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev. 2004;56:1825–1857.
   PubMed Web of Science ®Google Scholar
• Lin J. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab [Internet]. 2008;9:46–59. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-38849136513&partnerID=tZOtx3y1
   PubMed Web of Science ®Google Scholar
• de Lange EC. The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS [Internet]. 2013;10:12. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3602026&tool=pmcentrez&rendertype=abstract
   PubMedGoogle Scholar
• de Lange ECM, Hammarlund-Udenaes M. Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients. Clin Pharmacol Ther. 2015;97:380–394.
   PubMed Web of Science ®Google Scholar
• Lange ECMD, Brink WJVD, Yamamoto Y, et al. Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics. Expert Opin Drug Discov [Internet]. 2017;12:1–12. Available from: https://www.tandfonline.com/doi/full/10.1080/17460441.2017.1380623
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Välitalo PA, Berg D-JVD, et al. A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations. Pharm Res [Internet]. 2016. DOI:10.1007/s11095-016-2065-3.
   Google Scholar
• Loryan I, Sinha V, Mackie C, et al. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates. Mol Pharm. 2015;12:520–532.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Välitalo PA, Huntjens DR, et al. Predicting drug concentration-time profiles in multiple CNS compartments using a comprehensive physiologically-based pharmacokinetic model. CPT Pharmacomet Syst Pharmacol. 2017;6:765–777.
   PubMedGoogle Scholar
• Visser SAG, Smulders CJGM, Reijers BPR, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats. J Pharmacol Exp Ther [Internet]. 2002;302:1158–1167. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12183676
   PubMed Web of Science ®Google Scholar
• Danhof M, de Jongh J, De Lange ECM, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol. 2007;47:357–400.
   PubMed Web of Science ®Google Scholar
• Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003;31:510–518.
   PubMed Web of Science ®Google Scholar
• de Witte WEA, Vauquelin G, van der Graaf PH, et al. The influence of drug distribution and drug-target binding on target occupancy: the rate-limiting step approximation. Eur J Pharm Sci [Internet]. 2017;1–6. DOI:10.1016/j.ejps.2017.05.024.
   Web of Science ®Google Scholar
• Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21:457–478.
   PubMedGoogle Scholar
• Chien JY, Friedrich S, Heathman MA, et al. Pharmacokinetics/pharmacodynamics and the stages of drug development : role of modeling and simulation. 2005;7:E544–E559.
   Google Scholar
• Adolph E. Quantitative relations in the physiological constitutions of mammals. Science (80-.) 1949;109:579–585.
   PubMed Web of Science ®Google Scholar
• Bertalanffy LV. Quantitative laws in metabolism and growth. Q Rev Biol [Internet]. 1957;32:217–231. Available from: http://linksource.ebsco.com/FullText.aspx?linkout=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=mnh&AN=21800635&ErrorURL=http://linksource.ebsco.com/error.aspx
   PubMed Web of Science ®Google Scholar
• West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122–126.
   Google Scholar
• Zuideveld KP, van der Graaf PH, Peletier LA, et al. Allometric scaling of pharmacodynamic responses: application to 5-HT 1A receptor mediated responses from rat to man. Pharm Res. 2007;24:2031–2039.
   PubMed Web of Science ®Google Scholar
• Kantae V, Krekels EHJ, Ordas A, et al. Pharmacokinetic modeling of paracetamol uptake and clearance in zebrafish larvae: expanding the allometric scale in vertebrates with five orders of magnitude. Zebrafish [Internet]. 2016;13:504–510. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27632065
   PubMed Web of Science ®Google Scholar
• Westerhout J, Danhof M, Lange ECMD. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci. 2011;100:3577–3593.
   PubMed Web of Science ®Google Scholar
• Ball K, Bouzom F, Scherrmann J-M, et al. Physiologically based pharmacokinetic modelling of drug penetration across the blood–brain barrier—towards a mechanistic IVIVE-based approach. AAPS J [Internet]. 2013;15:913–932. Available from: http://link.springer.com/10.1208/s12248-013-9496-0
   PubMed Web of Science ®Google Scholar
• Westerhout J, Ploeger B, Smeets J, et al. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J. 2012;14:543–553.
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Olson ER, Cassidy MP, et al. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther. 2007;323:346–355.
   PubMed Web of Science ®Google Scholar
• Gosset JR, Beaumont K, Matsuura T, et al. A cross-species translational pharmacokinetic-pharmacodynamic evaluation of core body temperature reduction by the TRPM8 blocker PF-05105679. Eur J Pharm Sci [Internet]. 2017;0–1. DOI:10.1016/j.ejps.2017.06.009.
   Web of Science ®Google Scholar
• Gotta V, Yu Z, Cools F, et al. Application of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation. Pharmacol Res Perspect. 2016;4:1–17.
   Web of Science ®Google Scholar
• van den Brink W, Palic S, Köhler I, et al. Access to the CNS: biomarker strategies for dopaminergic treatments. Pharm Res. 2018;35:64.
   PubMed Web of Science ®Google Scholar
• Bianchi MT, Pathmanathan J, Cash SS. From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med Hypotheses [Internet]. 2009;72:297–305.
   PubMed Web of Science ®Google Scholar
• Xuan J, Pan G, Qiu Y, et al. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011;10:5433–5443.
   PubMed Web of Science ®Google Scholar
• López-Muñoz F, Baumeister AA, Hawkins MF, et al. The role of serendipity in the discovery of the clinical effects of psychotropic drugs: beyond of the myth. Actas Esp Psiquiatr. 2012;40:34–42.
   PubMed Web of Science ®Google Scholar
• Sun J, Xu H, Zhao Z. Network-assisted investigation of antipsychotic drugs and their targets. Chem Biodivers. 2012;9:900–910.
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov [Internet]. 2004;3:353–359. Available from: http://www.nature.com/doifinder/10.1038/nrd1346
   PubMed Web of Science ®Google Scholar
• Margineanu DG. Neuropharmacology beyond reductionism - A likely prospect. BioSystems [Internet]. 2016;141:1–9.
   PubMed Web of Science ®Google Scholar
• Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate, and GABA in schizophrenai: new evidence. Annu Rev Pharmacol Toxicol. 2001;41:237–260.
   PubMed Web of Science ®Google Scholar
• Greef JVD, Mcburney RN. Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov. 2005;4:961–968.
   PubMed Web of Science ®Google Scholar
• Kumar B, Prakash A, Ruhela RK, et al. Potential of metabolomics in preclinical and clinical drug development. Pharmacol Rep [Internet]. 2014;66:956–963.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Weinshilboum R. Pharmacometabolomics research network. metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine. Clin Pharmacol Ther [Internet]. 2015;98:71–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25871646
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007;12:934–945.
   PubMed Web of Science ®Google Scholar
• Lamers RJAN, Van Nesselrooij JHJ, Kraus VB, et al. Identification of an urinary metabolite profile associated with osteoarthritis. Osteoarthr Cartil. 2005;13:762–768.
   PubMed Web of Science ®Google Scholar
• van der Greef J, Adourian A, Muntendam P, et al. Lost in translation? Role of metabolomics in solving translational problems in drug discovery and development. Drug Discov Today Technol. 2006;3:205–211.
   PubMedGoogle Scholar
• Blais EM, Rawls KD, Dougherty BV, et al. Reconciled rat and human metabolic networks for comparative toxicogenomics and biomarker predictions. Nat Commun [Internet]. 2017;8:1–15.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0-the human metabolome database in 2013. Nucl Acids Res. 2013;41:801–807.
   PubMed Web of Science ®Google Scholar
• Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis [Internet]. 2009;35:165–176.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiat [Internet]. 2013;3:e223. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3566722&tool=pmcentrez&rendertype=abstract
   PubMed Web of Science ®Google Scholar
• Rozen S, Cudkowicz ME, Bogdanov M, et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics. 2005;1:101–108.
   PubMed Web of Science ®Google Scholar
• Jimhez-Jimcnez FJ, Molina A, Vargas C, et al. Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson ’ s disease. J Neurol Sci. 1996;141:39–44.
   PubMed Web of Science ®Google Scholar
• Brown M, Dunn WB, Ellis DI, et al. A metabolome pipeline : from concept to data to knowledge. Metabolomics. 2005;1.
   PubMed Web of Science ®Google Scholar
• Bartel J, Krumsiek J, Theis FJ. Statistical methods for the analysis of high-throughput metabolomics data. Comput Struct Biotechnol J [Internet]. 2013;4:e201301009. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3962125&tool=pmcentrez&rendertype=abstract
   PubMedGoogle Scholar
• Krumsiek J, Suhre K, Illig T, et al. Gaussian graphical modeling reconstructs pathway reactions from high-throughput metabolomics data. BMC Syst Biol. 2011;5:21.
   Web of Science ®Google Scholar
• Xia J, Wishart DS. MSEA: A web-based tool to identify biologically meaningful patterns in quantitative metabolomic data. Nucl Acids Res. 2010;38:71–77.
   PubMed Web of Science ®Google Scholar
• Danhof M. Systems pharmacology - Towards the modeling of network interactions. Eur J Pharm Sci [Internet]. 2016. DOI:10.1016/j.ejps.2016.04.027.
   PubMed Web of Science ®Google Scholar
• Jin JY, Almon RR, DuBois DC, et al. Modeling of corticosteroid pharmacogenomics in rat liver using gene microarrays. J Pharmacol Exp Ther. 2003;307:93–109.
   PubMed Web of Science ®Google Scholar
• Wang J, Reijmers ÆT, Chen ÆL. Systems toxicology study of doxorubicin on rats using ultra performance liquid chromatography coupled with mass spectrometry based metabolomics. Metabolomics. 2009;5:407–418.
   Google Scholar
• Lamers RJ, DeGroot J, Spies-Faber EJ, et al. Identification of disease- and nutrient-related metabolic fingerprints in osteoarthritic Guinea pigs. J Nutr. 2003;133:1776–1780.
   PubMed Web of Science ®Google Scholar
• ’T Hart BA, Vogels JTWE, Spijksma G, et al. 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J Neurol Sci. 2003;212:21–30.
   PubMed Web of Science ®Google Scholar
• Yao D, Shi X, Wang L, et al. Characterization of differential cocaine metabolism in mouse and rat through metabolomics-guided metabolite profiling. Drug Metab Dispos. 2013;41:79–88.
   PubMed Web of Science ®Google Scholar
• National Research Council (US). Committee on applications of toxicogenomics to cross-species extrapolation. Application of Toxicogenomics to Cross-Species Extrapolation: A Report of a Workshop; 2005.
   Google Scholar
• Kohler I, Hankemeier T, Graaf PHVD, et al. European Journal of Pharmaceutical Sciences Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine. Eur J Pharm Sci [Internet]. 2017;0–1. DOI: 10.1016/j.ejps.2017.05.018
   Web of Science ®Google Scholar
• Hasselt JGCV, Graaf PHVD. Towards integrative systems pharmacology models in oncology drug development. Drug Discov Today Technol [Internet]. 2015;15:1–8.
   PubMedGoogle Scholar
• Kantae V, Krekels EHJ, Esdonk MJV, et al. Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics [Internet]. 2017;13:9. Available from: http://link.springer.com/10.1007/s11306-016-1143-1
   PubMed Web of Science ®Google Scholar
• Ellero-Simatos S, Lewis JP, Georgiades A, et al. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacomet Syst Pharmacol [Internet]. 2014;3:e125. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25029353
   PubMedGoogle Scholar
• Rasmussen MA, Colding-Jørgensen M, Hansen LT, et al. Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma. Br J Clin Pharmacol. 2010;69:379–390.
   PubMed Web of Science ®Google Scholar
• van den Brink WJ, Elassaiss-Schaap J, Gonzalez-Amoros B, et al. Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats. Eur J Pharm Sci [Internet]. 2017;109:431–440. [cited 2017 Sep 13]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0928098717304888
   PubMed Web of Science ®Google Scholar
• Sorger PK, Allerheiligen SRB, Altmann RB, et al. Emergence of quantitative and systems pharmacology: a white paper. NIH QSP Work [Internet]. 2011;1–48. Available from: papers2://publication/uuid/135d6564-7ee8-4a97-ba4b-be47e3369b3b
   Google Scholar
• Iyengar R, Zhao S, Chung S-W, et al. Merging Systems Biology with Pharmacodynamics. Sci Transl Med. 2012;4:126ps7–126ps7.
   PubMed Web of Science ®Google Scholar
• Knight-Schrijver VR, Chelliah V, Cucurull-Sanchez L, et al. The promises of quantitative systems pharmacology modelling for drug development. Comput Struct Biotechnol J [Internet]. 2016;14:363–370.
   PubMed Web of Science ®Google Scholar
• Geerts H, Spiros A, Roberts P, et al. Has the time come for predictive computer modeling in CNS drug discovery and development? CPT Pharmacometrics Syst Pharmacol [Internet]. 2012;1:e16. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3600733&tool=pmcentrez&rendertype=abstract
   PubMedGoogle Scholar
• de Lange ECM, Danhof M, de Boer AG, et al. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood–brain barrier. Brain Res Rev [Internet]. 1997;25:27–49. Available from: http://www.sciencedirect.com/science/article/pii/S0165017397000143
   PubMed Web of Science ®Google Scholar
• de Lange ECM. Microdialysis in drug development. Microdialysis Drug Dev [Internet]. 2013;13–33. Available from: http://link.springer.com/10.1007/978-1-4614-4815-0
   Google Scholar
• Qu Y, Olson L, Jiang X, et al. Evaluating PK/PD relationship of CNS drug by using liquid chromtography/tandem mass spectrometry coupled to in vivo microdialysis. In: J Prasain, editor. Tandem mass spectrometry - Applications and principles. Rijeka: InTech; 2012. p. 421–440.
   Google Scholar
• Ravenstijn PG, Drenth H-J, O’Neill MJ, et al. Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson’s disease. Fluids Barriers CNS [Internet]. 2012;9:4. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3298802&tool=pmcentrez&rendertype=abstract
   PubMedGoogle Scholar
• Huang M, Panos JJ, Kwon S, et al. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT) 2A and da D2 antagonism and 5-HT1A partial agonism. J Neurochem. 2014;128:938–949.
   PubMed Web of Science ®Google Scholar
• Kao C-Y, Anderzhanova E, Asara JM, et al. NextGen brain microdialysis: applying modern metabolomics technology to the analysis of extracellular fluid in the central nervous system. Mol Neuropsychiatry. 2015;1:60–67.
   PubMedGoogle Scholar
• Goetghebeur PJ, Swartz JE. True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence. J Psychopharmacol [Internet]. 2016;30:586–594. Available from: http://jop.sagepub.com/cgi/doi/10.1177/0269881116645269
   PubMed Web of Science ®Google Scholar
• Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45–73.
   PubMed Web of Science ®Google Scholar
• Greef JVD, Martin S, Juhasz P, et al. The art and practice of systems biology in medicine : mapping patterns of relationships. J Proteome Res. 2007;6:1540–1559.
   PubMed Web of Science ®Google Scholar
• Chokkathukalam A, Kim D, Barrett MP, et al. Stable isotope-labeling studies in metabolomics : new insights into structure and dynamics of metabolic networks. Bioanalysis. 2014;6:511–524.
   PubMed Web of Science ®Google Scholar
• Bueschl C, Krska R, Kluger B, et al. Isotopic labeling-assisted metabolomics using LC-MS. Anal Bioanal Chem. 2013;405:27–33.
   PubMed Web of Science ®Google Scholar